New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
07:23 EDTPTCTPTC Therapeutics: EMA adopted negative opinion on MAA for Atuluren approval
PTC Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion on the company's marketing authorization application for conditional approval of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy. The response from the CHMP is consistent with the company's previous guidance concerning the substantial risks regarding conditional EMA approval and underscores the importance of PTC's work in completing the ongoing confirmatory Phase 3 clinical trial. In April 2013, PTC initiated a 48-week, 220-patient confirmatory Phase 3 clinical trial of ataluren for the treatment of nmDMD. The trial is on track to complete enrollment in mid-2014 with top-line data expected in mid-2015. PTC intends to request a re-examination of the CHMP opinion with a final outcome expected in the second quarter of 2014, when the confirmatory study is expected to be more fully enrolled.
News For PTCT From The Last 14 Days
Check below for free stories on PTCT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
08:52 EDTPTCTPTC Therapeutics price target raised to $43 from $34 at Roth Capital
Subscribe for More Information
August 12, 2014
09:57 EDTPTCTPTC Therapeutics management to meet with Oppenheimer
Meeting to be held in Toronto on August 18 hosted by Oppenheimer.
August 11, 2014
15:27 EDTPTCTWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use